53378-75-9

Basic information

• Product Name: 1,5-Pentanediol, 3-(2-hydroxyethyl)-
• Synonyms: tris(2-hydroxyethyl)methane;triethanolmethane;1,5-Pentanediol,3-(2-hydroxyethyl);3-(2-Hydroxy-aethyl)-pentan-1,5-diol;tri-(2-hydroxyethyl)methane;3-(2-hydroxy-ethyl)-pentane-1,5-diol
• CAS NO: 53378-75-9
• Molecular Formula: C7H16O3
• Molecular Weight: 148.202
• Mol File: 53378-75-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 189-191 °C(Press: 2 Torr)
• Density: 1.087 g/cm3(Temp: 19 °C)
• CAS DataBase Reference: 1,5-Pentanediol, 3-(2-hydroxyethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,5-Pentanediol, 3-(2-hydroxyethyl)-(53378-75-9)
• EPA Substance Registry System: 1,5-Pentanediol, 3-(2-hydroxyethyl)-(53378-75-9)

Safety Data

• Hazardous Substances Data: 53378-75-9(Hazardous Substances Data)

Upstream product

• 87986-82-1 tris(2-acetoxyethyl)methane 

Downstream Products

• 489427-21-6 4-{5-(2-hydroxyimino-1,1-dimethyl-propylamino)-3-[2-(2-hydroxyimino-1,1-dimethyl-propylamino)-ethyl]-pentylcarbamoyl}-thiobutyric acid 2,3,5,6-tetrafluoro-phenyl ester 
• 53378-76-0 Diethyl-5-brom-3-(2-bromethyl)-pentylphosphonat 
• 6299-66-7 4-ethylhexanoic acid 
• 100-76-5 Quinuclidine 
• 26456-63-3 3-vinylpenta-1,4-diene 

Relevant articles and documents

Diagnostic imaging agents with mmp inhibitory activity

The present invention relates to the field of diagnostic imaging. Specifically, the invention relates to the diagnostic imaging of diseases where specific matrix metalloproteinases are known to be involved. One embodiment of the invention is a compound having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the diagnostic imaging agent of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the diagnostic imaging agents of the invention and kits for the preparation of the pharmaceutical composition of the invention. The pharmaceutical composition of the invention may be used in the diagnosis of diseases where specific matrix metalloproteinases are known to be involved.